MedPath

Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients

Completed
Conditions
Tachycardia
Septic Shock
Interventions
Registration Number
NCT02188888
Lead Sponsor
University of Roma La Sapienza
Brief Summary

Clinical study suggests that beta-blockers by decreasing heart rate together with an increase in stroke volume do not negatively affect cardiac output allowing an economization of cardiac work and oxygen consumption in patients with septic shock. Whether this hemodynamic profile leads to an amelioration of myocardial performance is still unclear. The objective of the present study is therefore to elucidate whether a reduction in heart rate with esmolol is associated to an improvement of cardiac efficiency in patients with septic shock who remained tachycardic after hemodynamic optimization.

Detailed Description

After 24-36 hours of initial hemodynamic stabilization, 44 septic shock patients with heart rate \> of 95 bpm and requiring norepinephrine to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation,will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg. To investigate myocardial performance, we will simultaneously assess LV ejection fraction (LVEF), tricuspidal annular plane solid excursion (TAPSE) by echocardiography, the dP/dt MAX and the cardiac cycle efficiency (CCE) both estimated from the arterial pressure waveform. Finally we will analyze changes in static arterial elastance. Data will be obtained at baseline and after four hours once achieved the predefined heart rate threshold.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria
  • septic shock criteria
  • presence of heart rate > 95 bpm.
Exclusion Criteria
  • Pregnancy
  • age < 18

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Tachycardic patientsesmololPatients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
Primary Outcome Measures
NameTimeMethod
heart rateover a period of four hours
Secondary Outcome Measures
NameTimeMethod
echocardiographyover a period of four hours

LV ejection fraction (LVEF) and tricuspidal annular plane solid excursion (TAPSE)

static arterial elastanceover a period of four hours

Trial Locations

Locations (1)

Department of Anesthesiology and Intensive care of the University of Rome La Sapienza

🇮🇹

Rome, Italy

© Copyright 2025. All Rights Reserved by MedPath